A detailed history of Quest Partners LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Quest Partners LLC holds 579 shares of KRYS stock, worth $83,155. This represents 0.01% of its overall portfolio holdings.

Number of Shares
579
Previous 1,663 65.18%
Holding current value
$83,155
Previous $300 Million 73.46%
% of portfolio
0.01%
Previous 0.03%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Jul 31, 2025

SELL
$123.36 - $181.0 $133,722 - $196,204
-1,084 Reduced 65.18%
579 $79.6 Million
Q1 2025

May 14, 2025

SELL
$142.64 - $194.44 $193,562 - $263,855
-1,357 Reduced 44.93%
1,663 $300 Million
Q4 2024

Feb 07, 2025

BUY
$156.64 - $199.61 $254,070 - $323,767
1,622 Added 116.02%
3,020 $473 Million
Q3 2024

Nov 07, 2024

BUY
$174.7 - $213.66 $177,145 - $216,651
1,014 Added 264.06%
1,398 $254 Million
Q2 2024

Aug 06, 2024

BUY
$153.12 - $183.64 $58,798 - $70,517
384 New
384 $70.5 Million
Q4 2023

Feb 09, 2024

BUY
$96.0 - $128.29 $98,112 - $131,112
1,022 New
1,022 $127 Million

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $3.69B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Quest Partners LLC Portfolio

Follow Quest Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quest Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quest Partners LLC with notifications on news.